Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vogelzang, N. J.
Right arrow Articles by Paoletti, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogelzang, N. J.
Right arrow Articles by Paoletti, P.
Related Articles
Right arrowRelated Correspondence
Journal of Clinical Oncology, Vol 21, Issue 14 (July), 2003: 2636-2644
© 2003 American Society for Clinical Oncology

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James Symanowski, Claude Denham, E. Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti

From the University of Chicago Cancer Research Center, Chicago, IL; Eli Lilly and Company, Indianapolis, IN; US Oncology, Dallas, TX; Allgemeines Krankenhaus Harburg, Hamburg; Krankenhaus Großhansdorf, Großhansdorf; and Thoraxklinik-Rohrbach, Heidelberg, Germany; Institut Gustave Roussy, Villejuif, France; Royal Prince Alfred Hospital, Camperdown, Australia; and Hacettepe University Medical Faculty, Ankara, Turkey.

Address reprint requests to Nicholas J. Vogelzang, MD, University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637; email: nvogelza{at}medicine.bsd.uchicago.edu.

Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone.

Patients and Methods: Chemotherapy-naive patients who were not eligible for curative surgery were randomly assigned to receive pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1, or cisplatin 75 mg/m2 on day 1. Both regimens were given intravenously every 21 days.

Results: A total of 456 patients were assigned: 226 received pemetrexed and cisplatin, 222 received cisplatin alone, and eight never received therapy. Median survival time in the pemetrexed/cisplatin arm was 12.1 months versus 9.3 months in the control arm (P = .020, two-sided log-rank test). The hazard ratio for death of patients in the pemetrexed/cisplatin arm versus those in the control arm was 0.77. Median time to progression was significantly longer in the pemetrexed/cisplatin arm: 5.7 months versus 3.9 months (P = .001). Response rates were 41.3% in the pemetrexed/cisplatin arm versus 16.7% in the control arm (P < .0001). After 117 patients had enrolled, folic acid and vitamin B12 were added to reduce toxicity, resulting in a significant reduction in toxicities in the pemetrexed/cisplatin arm.

Conclusion: Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cisplatin alone in patients with malignant pleural mesothelioma. Addition of folic acid and vitamin B12 significantly reduced toxicity without adversely affecting survival time.

Supported by a grant from Eli Lilly and Company.


Related Correspondence

  • Need for Further Information on Pemetrexed Study
    Yossef Aelony
    JCO 2004 22: 4234-4235 [Full Text]


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
M. K. B. Parmar, Friederike. M.-S. Barthel, M. Sydes, R. Langley, R. Kaplan, E. Eisenhauer, M. Brady, N. James, M. A. Bookman, A.-M. Swart, et al.
Speeding up the Evaluation of New Agents in Cancer
J Natl Cancer Inst, September 3, 2008; 100(17): 1204 - 1214.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Fukazawa, J. Matsuoka, Y. Naomoto, Y. Maeda, M. L. Durbin, and N. Tanaka
Malignant Pleural Mesothelioma-Targeted CREBBP/EP300 Inhibitory Protein 1 Promoter System for Gene Therapy and Virotherapy
Cancer Res., September 1, 2008; 68(17): 7120 - 7129.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. R. Simon, C. F. Verschraegen, P. A. Janne, C. J. Langer, A. Dowlati, S. M. Gadgeel, K. Kelly, G. P. Kalemkerian, A. M. Traynor, G. Peng, et al.
Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial
J. Clin. Oncol., July 20, 2008; 26(21): 3567 - 3572.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, et al.
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 20, 2008; 26(21): 3543 - 3551.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
C. Aigner, M. A. R. Hoda, G. Lang, S. Taghavi, G. Marta, and W. Klepetko
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 204 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Ohe, Y. Ichinose, K. Nakagawa, T. Tamura, K. Kubota, N. Yamamoto, S. Adachi, Y. Nambu, T. Fujimoto, Y. Nishiwaki, et al.
Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2008; 14(13): 4206 - 4212.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. W. van Sandick, I. Kappers, P. Baas, R. L. Haas, and H. M. Klomp
Surgical Treatment in the Management of Malignant Pleural Mesothelioma: A Single Institution's Experience
Ann. Surg. Oncol., June 1, 2008; 15(6): 1757 - 1764.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Nakagawa, K. Yamazaki, H. Kunitoh, T. Hida, K. Gemba, T. Shinkai, Y. Ichinose, S. Adachi, Y. Nambu, N. Saijo, et al.
Efficacy and Safety of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma: A Phase I/II Study in Japanese Patients
Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 339 - 346.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A Chapman, S Mulrennan, B Ladd, and M F Muers
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
Thorax, May 1, 2008; 63(5): 435 - 439.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
A. L Jackman
Exploiting Folate Pathways and Transporters for the Management and Treatment of Cancer
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 101 - 108.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Jassem, R. Ramlau, A. Santoro, W. Schuette, A. Chemaissani, S. Hong, J. Blatter, S. Adachi, A. Hanauske, and C. Manegold
Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma
J. Clin. Oncol., April 1, 2008; 26(10): 1698 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Anraku, K. S. Cunningham, Z. Yun, M.-S. Tsao, L. Zhang, S. Keshavjee, M. R. Johnston, and M. de Perrot
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 823 - 829.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Janne, G. R. Simon, C. J. Langer, R. N. Taub, A. Dowlati, P. Fidias, M. Monberg, C. Obasaju, and H. Kindler
Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naive Malignant Pleural Mesothelioma
J. Clin. Oncol., March 20, 2008; 26(9): 1465 - 1471.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. M. Flores, H. I. Pass, V. E. Seshan, J. Dycoco, M. Zakowski, M. Carbone, M. S. Bains, and V. W. Rusch
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients
J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 620 - 626.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. An, D. C. Drummond, S. Wilson, D. B. Kirpotin, S. L. Nishimura, V. C. Broaddus, and B. Liu
Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
Mol. Cancer Ther., March 1, 2008; 7(3): 569 - 578.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
M. Okada, T. Mimura, C. Ohbayashi, T. Sakuma, T. Soejima, and N. Tsubota
Radical surgery for malignant pleural mesothelioma: results and prognosis
Interactive CardioVascular and Thoracic Surgery, February 1, 2008; 7(1): 102 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Castagneto, M. Botta, E. Aitini, F. Spigno, D. Degiovanni, O. Alabiso, M. Serra, A. Muzio, R. Carbone, R. Buosi, et al.
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
Ann. Onc., February 1, 2008; 19(2): 370 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
A. Nakas, A. E. Martin Ucar, J. G. Edwards, and D. A. Waller
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma
Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 83 - 88.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
H. L. Kindler, R. Bueno, and J. R. Testa
New Biomarkers, Surgical Controversies, and Rationally Targeted Therapies for Malignant Mesothelioma
ASCO Educational Book, January 1, 2008; 2008(1): 354 - 361.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. de Marinis and F. Grossi
Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Oncologist, January 1, 2008; 13(suppl_1): 14 - 20.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. E. Stinchcombe and M. A. Socinski
Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer
Oncologist, January 1, 2008; 13(suppl_1): 28 - 36.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
British Thoracic Society Standards of Care Committ
BTS statement on malignant mesothelioma in the UK, 2007
Thorax, November 1, 2007; 62(Suppl_2): ii1 - ii19.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Li, S. Yano, H. Ogino, W. Wang, H. Uehara, Y. Nishioka, and S. Sone
The Therapeutic Efficacy of Anti Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice
Clin. Cancer Res., October 1, 2007; 13(19): 5918 - 5925.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S. Shewach and T. S. Lawrence
Antimetabolite Radiosensitizers
J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. H. Sterman, A. Recio, R. G. Carroll, C. T. Gillespie, A. Haas, A. Vachani, V. Kapoor, J. Sun, R. Hodinka, J. L. Brown, et al.
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
Clin. Cancer Res., August 1, 2007; 13(15): 4456 - 4466.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. S. Tsao, D. He, B. Saigal, S. Liu, J. J. Lee, S. Bakkannagari, N. G. Ordonez, W. K. Hong, I. Wistuba, and F. M. Johnson
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
Mol. Cancer Ther., July 1, 2007; 6(7): 1962 - 1972.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W Weder, R. Stahel, J Bernhard, S Bodis, P Vogt, P Ballabeni, D Lardinois, D Betticher, R Schmid, R Stupp, et al.
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
Ann. Onc., July 1, 2007; 18(7): 1196 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Chattopadhyay, R. Tamari, S. H. Min, R. Zhao, E. Tsai, and I. D. Goldman
Commentary: A Case for Minimizing Folate Supplementation in Clinical Regimens with Pemetrexed Based on the Marked Sensitivity of the Drug to Folate Availability
Oncologist, July 1, 2007; 12(7): 808 - 815.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. L. Ceresoli, C. Gridelli, and A. Santoro
Multidisciplinary Treatment of Malignant Pleural Mesothelioma
Oncologist, July 1, 2007; 12(7): 850 - 863.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. L. Garland, C. Rankin, D. R. Gandara, S. E. Rivkin, K. M. Scott, R. B. Nagle, A. J.P. Klein-Szanto, J. R. Testa, D. A. Altomare, and E. C. Borden
Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study
J. Clin. Oncol., June 10, 2007; 25(17): 2406 - 2413.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. Treasure and M. Utley
Ten traps for the unwary in surgical series: A case study in mesothelioma reports
J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1414 - 1418.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B.-D. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, M. Gregoire, H. Porte, M.-C. Copin, and P. Lassalle
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
Clin. Cancer Res., May 15, 2007; 13(10): 2928 - 2935.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. H. Takimoto, L. A. Hammond-Thelin, J. E. Latz, L. Forero, M. Beeram, B. Forouzesh, J. de Bono, A. W. Tolcher, A. Patnaik, P. Monroe, et al.
Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer
Clin. Cancer Res., May 1, 2007; 13(9): 2675 - 2683.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Azzoli, L. M. Krug, J. Gomez, V. A. Miller, M. G. Kris, M. S. Ginsberg, R. Henry, J. Jones, L. Tyson, M. Dunne, et al.
A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors
Clin. Cancer Res., May 1, 2007; 13(9): 2692 - 2698.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Malempati, H. S. Nicholson, J. M. Reid, S. M. Blaney, A. M. Ingle, M. Krailo, L. C. Stork, A. S. Melemed, R. McGovern, S. Safgren, et al.
Phase I Trial and Pharmacokinetic Study of Pemetrexed in Children With Refractory Solid Tumors: The Children's Oncology Group
J. Clin. Oncol., April 20, 2007; 25(12): 1505 - 1511.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Boeck, K Weigang-Kohler, M Fuchs, E Kettner, D Quietzsch, J Trojan, O Stotzer, S Zeuzem, F Lordick, C-H Kohne, et al.
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial
Ann. Onc., April 1, 2007; 18(4): 745 - 751.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Lucchi, A. Chella, F. Melfi, P. Dini, M. Ambrogi, L. Fino, G. Fontanini, and A. Mussi
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma
Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 529 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Chattopadhyay, R. G. Moran, and I. D. Goldman
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Y. Seiwert, P. P. Connell, A. M. Mauer, P. C. Hoffman, C. M. George, L. Szeto, R. Salgia, K. E. Posther, B. Nguyen, D. J. Haraf, et al.
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung or Esophageal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 515 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. K. Rowinsky, M. Beeram, L. A. Hammond, G. Schwartz, J. De Bono, B. Forouzesh, Q. Chu, J. E. Latz, S. Hong, W. John, et al.
A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
Clin. Cancer Res., January 15, 2007; 13(2): 532 - 539.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
S. M. Tyszko, G. D. Marano, R. J. Tallaksen, and K. A. Gyure
Best Cases from the AFIP: Malignant Mesothelioma
RadioGraphics, January 1, 2007; 27(1): 259 - 264.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Dittrich, L. Petruzelka, P. Vodvarka, M. Gneist, F. Janku, T. Kysela, A. Melemed, J. Latz, L. Simms, and K. Krejcy
A Phase I Study of Pemetrexed (ALIMTA) and Cyclophosphamide in Patients with Locally Advanced or Metastatic Breast Cancer
Clin. Cancer Res., December 1, 2006; 12(23): 7071 - 7078.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
Spoken sessions
Thorax, December 1, 2006; 61(suppl_2): ii3 - ii56.
[Full Text] [PDF]

Home page
 Ann OncolHome page
R Hassan, R Alexander, K Antman, P Boffetta, A Churg, D Coit, P Hausner, R Kennedy, H Kindler, M Metintas, et al.
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference
Ann. Onc., November 1, 2006; 17(11): 1615 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Socinski, C. Weissman, L. L. Hart, J. T. Beck, J. K. Choksi, J. P. Hanson, D. Prager, M. J. Monberg, Z. Ye, and C. K. Obasaju
Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer
J. Clin. Oncol., October 20, 2006; 24(30): 4840 - 4847.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Can {blacktriangledown}pemetrexed help in malignant mesothelioma?
DTB, October 1, 2006; 44(10): 77 - 80.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. L. Ceresoli, A. Chiti, P. A. Zucali, M. Rodari, R. F. Lutman, S. Salamina, M. Incarbone, M. Alloisio, and A. Santoro
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
J. Clin. Oncol., October 1, 2006; 24(28): 4587 - 4593.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Chattopadhyay, R. Zhao, E. Tsai, V. L. Schramm, and I. D. Goldman
The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
Mol. Cancer Ther., October 1, 2006; 5(10): 2549 - 2555.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Sweeney, B. J. Roth, F. F. Kabbinavar, D. J. Vaughn, M. Arning, R. E. Curiel, C. K. Obasaju, Y. Wang, S. J. Nicol, and D. S. Kaufman
Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium
J. Clin. Oncol., July 20, 2006; 24(21): 3451 - 3457.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Flynn, R. W. Berg, T. Wong, M. van Aken, M. D. Vincent, M. Fukushima, and J. Koropatnick
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.
Mol. Cancer Ther., June 1, 2006; 5(6): 1423 - 1433.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Hendricksen, P. M.J. Moonen, A. G. van der Heijden, J. Molkenboer-Kuenen, C. A. Hulsbergen-van de Kaa, and J. A. Witjes
Potential and Toxicity of Intravesical Pemetrexed: a Preclinical Study in Pigs
Clin. Cancer Res., April 15, 2006; 12(8): 2597 - 2601.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. G. Richards, L. Zellos, R. Bueno, M. T. Jaklitsch, P. A. Janne, L. R. Chirieac, B. Y. Yeap, R. J. Dekkers, P. M. Hartigan, L. Capalbo, et al.
Phase I to II Study of Pleurectomy/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma
J. Clin. Oncol., April 1, 2006; 24(10): 1561 - 1567.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
R. Maruyama, M. Sakai, T. Nakamura, R. Suemitsu, T. Okamoto, H. Wataya, K. Nishiyama, T. Kamei, and Y. Ichinose
Triplet Chemotherapy for Malignant Pericardial Mesothelioma: A Case Report
Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 245 - 248.
[Abstract] [Full Text] [PDF]

Home page